Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Ankley who wrote (3437)	7/18/1998 9:51:00 PM
From: R>G>	Respond to of 5402

One of the countrys best doctors!!! I believe Hillel Laks M.D. is a rare find for Dr. Drees and Sanguine. Makes for a great team, when your surrounded with outstanding talent. Very happy he is on our side. Don't know where you find all this stuff, but I love it. Thanks again Bob

To: Mike Ankley who wrote (3437)	7/18/1998 10:05:00 PM
From: General J	Read Replies (1) \| Respond to of 5402

Hey Mike you are leaving Old forthright in the dust.....You guys are discrediting him, its suppose to be the other way around...Old Forthright probably won't get a check from his North of the border employer if you guys keep on at this rate........ Red Blooded Americans, I love it!!!!!!!!!!!!!!!

To: Mike Ankley who wrote (3437)	7/19/1998 7:26:00 PM
From: Prospector	Respond to of 5402

To: Prospector (who wrote...) From: Mike Ankley Sunday, Jul 19 1998 6:42PM ET Hi Prospector: Here's the list of questions in their original format: 1. What is Dr. Drees anticipated market capture of the stated 20 billion per year.MARKET CAPTURE EST..10% IN 5 YEARS = 1,800,000,000/YEAR. 2. Worldwide market has been posted at 20 billion / year. Ignoring inflation: ALL MARKET ESTIMATES ARE IN 1998, NO INFLATION, WORLD POPULATION GROW 5-10% / YEAR a. with the worldwide population growing what effect, if any, would that have on the 20 billion? b. with overall population aging (yuppies getting older) what effect, if any, would that have on the 20 billion? c. with developing nations getting better medical care each year, what effect does that have on the 20 billion. So then, ignoring inflation, what is the annual rate of increase in the 20 billion given the above factors and others like them. 3. What are the various applications for which Sanguine is trying for FDA approval. I had heard there were approx. 80 possible applications, out of which Sanguine would only be trying for 2, I believe. Question: what are these 2, and also what are the other major applications that Sanguine will not be applying for approval? Also, given approval - would there be an exploitable market for any of the following: a. sports (aerobic exercise) b. scuba diving (avoid the bends) c. high altitude work d. mountain climbing e. fire fighting (breath PFC instead of smoky air) f. mining g. emergency first aid kits 150 POSSIBLE APPLICATIONS,, SGNC WILL TRY FOR 1 OR 2 AT A TIME FIRST 2 ANGIOPLASTY AND CARDIOPLGIA, THEN TRANSFUSION WHICH IS 80% OF MARKET. SPORTS, SCUBA DIVING, HIGH ALTITIDE, MAOUNTAIN CLIMBING, FIRE FIGHTING, MINING, EMERGENCY ARE ALL MARKETS FOR PHER-02. 4. Assuming FDA gives approval again, how reluctant will doctors be to switch from real blood transfusions to artifical blood transfusions. Or, if proven to be extremely safe and reliable, would doctors be more likely to give an articial blood transfusion as some type of added insurance, where previously they would have avoided a transfusion due to inherent real blood infection risks? SOME RELUCTANCE TO SWITH, BUT MALPRACTICE RISKS WILL HASTEN SWITCHING BY DOCTORS AND HOSPITALS. SINCE PHER-02 HAS NO INFECTION RISK, MD'S WILL PREFER IT TO HUMAN BLOOD TRANSFUSIONS. 5. In Green Cross's first generation testing, how long did the individual FDA phases take (e.g. animal, human, etc.) IN GREEN CROSS 1ST GENERATION TEST, FDA PHASE TOOK 3 YEARS FOR ANIMAL AND 5 YEARS FOR HUMAN. 6. Oxygent's product has been stated to on carry oxygen for approx 6-10 hrs (forget exact number). Is this really insufficient for most typical transfusion cases that they are not a real competitor of Sanguine due to Sanguine's increased oxygen carrying capabilities? OXYGENT HAS FAILED EUROPEAN AND U.S. CLINICAL TRIALS. THEY USE A DIFFERANT PFC THAN SGNC AND OUR 1/2 LIFE IS LONGER.